Skip to main content
Fig. 2 | Acta Neuropathologica Communications

Fig. 2

From: Combination of alpha-synuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophy

Fig. 2

Combined treatment reduces α-syn accumulation in MBP-α-syn transgenic mice. a-c Representative images of α-syn immunostaining and cell counts in neocortex (a), corpus callosum (b) and striatum (c) of non-tg and MBP-α-syn tg mice treated with LV-control or LV-CD5-D5-ApoB, and vehicle or lenalidomide. d Immunoblot and densitometric analysis of α-syn in the soluble fraction of protein extracts from non-tg and MBP-α-syn tg mice treated with LV-control or LV-CD5-D5-ApoB, and vehicle or lenalidomide. Significant results of three mice per group are shown. e Immunoblot and densitometric analysis of α-syn in the insoluble fraction of protein extracts from non-tg and MBP-α-syn tg mice treated with LV-control or LV-CD5-D5-ApoB, and vehicle or lenalidomide. Significant results of three mice per group are shown. f ELISA analysis of human α-syn levels in the soluble fraction of protein extracts from non-tg and MBP-α-syn tg mice treated with LV-control or LV-CD5-D5-ApoB, and vehicle or lenalidomide. Results are presented as average ± SEM. *** p < 0.001 when comparing vehicle/LV-control-treated non-tg mice to vehicle/LV-control-treated tg mice. # p < 0.05, ## p < 0.01 and ### p < 0.001 when comparing vehicle/LV-control-treated tg mice to single or multi-treated tg mice. Scale bar = 25 μm

Back to article page